USFDA20 May 2026, 10:11 pm
Strides Pharma: US-FDA Issues Form 483 With Five Observations
AI Summary
The USFDA conducted a routine cGMP inspection at Strides Pharma Science Ltd's Bangalore facility from May 12, 2026, to May 20, 2026. At the conclusion of the inspection, the U.S. FDA issued a Form 483 with five observations. The company will respond to the FDA within the stipulated time.
Key Highlights
- USFDA inspected Strides Pharma's Bangalore facility.
- The inspection took place from May 12 to May 20, 2026.
- USFDA issued a Form 483 with five observations.
- Strides Pharma will respond to the FDA within the given timeframe.